Mild Cognitive Impairment

The power of composite tests to track Alzheimer’s disease progression

Streamlining dementia diagnosis with digital biomarkers

Trends in the use of surrogate biomarkers during clinical trials

Digital markers detect changes in neurocognitive performance in those with vs without hearing loss

Mechanistic links between depressive symptoms and cognitive deficits

Assessing depressive symptoms in dementia screening

Comparing the performance of blood-based amyloid and tau assays

Phase II trial of AR1001 as a potential treatment for Alzheimer’s disease

Depressive symptom assessment can accurately detect cognitive decline

Primary care digital screening tool for Alzheimer’s disease

Clinical robustness of CSF pTau/Aβ42 ratio for Alzheimer’s disease diagnosis

Promise of microRNAs as Alzheimer’s disease markers

The regulatory role of nicotinic receptors in cognitive functioning

Mild behavioral impairment is associated with abnormal AD CSF biomarker profiles in MCI

How effective are cholinergic agents beyond MCI?

Clinical implementations of AlzoSure Predict